OR analysis of FGF21 for the risk of DR and STDR
| FGF21* | DR | STDR | ||||||||||
| OR (95% CI) | P value | Age-adjusted, sex-adjusted OR (95% CI) | P value | Multivariable-adjusted OR (95% CI)† | P value | OR (95% CI) | P value | Age-adjusted, sex-adjusted OR (95% CI) | P value | Multivariable-adjusted OR (95% CI)† | P value | |
| Q1 | 1 | 0.00 | 1 | 0.00 | 1 | 0.00 | 1 | 0.00 | 1 | 0.00 | 1 | 0.00 |
| Q2 | 2.21 (0.83 to 1.76) | 0.42 | 2.34 (0.88 to 1.90) | 0.19 | 1.95 (0.82 to 2.49) | 0.20 | 4.64 (0.72 to 6.74) | 0.24 | 4.95 (0.83 to 6.24) | 0.11 | 4.52 (0.48 to 5.79) | 0.45 |
| Q3 | 4.63 (1.09 to 6.44) | 0.01 | 5.76 (1.21 to 2.80) | 0.00 | 4.74 (1.13 to 3.75) | 0.02 | 5.58 (0.16 to 8.79) | 0.30 | 6.78 (0.83 to 8.98) | 0.26 | 7.67 (0.52 to 8.38) | 0.37 |
| Q4 | 6.98 (1.98 to 11.50) | 0.00 | 8.62 (5.28 to 5.66) | 0.00 | 7.56 (1.48 to 5.91) | 0.00 | 10.67 (7.82 to 25.53) | 0.00 | 10.22 (5.25 to 15.06) | 0.00 | 9.10 (5.70 to 15.79) | 0.00 |
*FGF21 (pg/mL) in quartiles: quartile 1 (Q1, <388), quartile 2 (Q2, 388–455), quartile 3 (Q3, 456–579), quartile 4 (Q4, >580).
†Adjusted for age (years), sex (men, women), duration of diabetes (year), body mass index (kg/m2), systolic blood pressure (mm Hg); diastolic blood pressure (mm Hg); smoking (no, yes), drinking (no, yes), coronary artery disease (no, yes), cerebral infraction (no, yes), fasting plasma glucose (mmol/L), 2-hour postprandial blood glucose (mmol/L), glycosylated hemoglobin (%), glycosylated serum protein (%), blood urea nitrogen (mmol/L), serum creatinine (μmol/L), uric acid (μmol/L), total cholesterol (mmol/L), triglyceride (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L).
DR, diabetic retinopathy; FGF21, fibroblast growth factor 21; STDR, sight-threatening diabetic retinopathy.